Greenleaf Trust Lowers Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Greenleaf Trust lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 53.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 2,231 shares of the medical equipment provider's stock after selling 2,612 shares during the period. Greenleaf Trust's holdings in Zimmer Biomet were worth $203,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC bought a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $204,000. NBC Securities Inc. raised its stake in shares of Zimmer Biomet by 176,700.0% during the 1st quarter. NBC Securities Inc. now owns 1,768 shares of the medical equipment provider's stock worth $200,000 after acquiring an additional 1,767 shares in the last quarter. OLD National Bancorp IN bought a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $207,000. Wesbanco Bank Inc. raised its stake in shares of Zimmer Biomet by 0.8% during the 1st quarter. Wesbanco Bank Inc. now owns 20,012 shares of the medical equipment provider's stock worth $2,265,000 after acquiring an additional 163 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in shares of Zimmer Biomet by 33.9% during the 1st quarter. Farther Finance Advisors LLC now owns 7,300 shares of the medical equipment provider's stock worth $820,000 after acquiring an additional 1,849 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the company's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares of the company's stock, valued at approximately $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.70% of the company's stock.

Zimmer Biomet Price Performance

Shares of ZBH opened at $100.81 on Monday. The firm has a market capitalization of $19.97 billion, a PE ratio of 24.53, a price-to-earnings-growth ratio of 2.32 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The company's fifty day moving average price is $100.87 and its 200-day moving average price is $98.62.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same period in the previous year, the company earned $2.01 earnings per share. The business's quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet's dividend payout ratio is presently 23.36%.

Analysts Set New Price Targets

Several research firms recently commented on ZBH. Rothschild Redb upgraded shares of Zimmer Biomet to a "strong-buy" rating in a research note on Thursday, September 18th. UBS Group boosted their price objective on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research note on Friday, August 8th. Rothschild & Co Redburn assumed coverage on shares of Zimmer Biomet in a report on Thursday, September 18th. They issued a "buy" rating and a $130.00 price target for the company. Royal Bank Of Canada boosted their price objective on shares of Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Finally, Roth Capital reissued a "buy" rating on shares of Zimmer Biomet in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of "Hold" and a consensus target price of $112.44.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.